The stock Price is showing that "50 day, 100 day, and 200 day" average price is about $75. The price will converge to $75.00 soon enough. It is a great company and them giving up on their HEP C product development speaks volume of their intent in the future. IMHO. Hint, Hint, Hint.
When VX-661 and Kalydeco were dosed together, the lung function for 551/508 CFers increased by 4.6% on top of the benefit Kalydeco alone can already deliver. This is another indication that VX-661 can act on 508 allele and make it work. This is also another indication that VX-809 which is similar to VX-661 in action mechanism repairs 508 CFTR and send it to the cell membrane.